These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 29181717)

  • 1. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
    Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
    Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
    Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
    J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
    Davis BA; Aminawung JA; Abu-Khalaf MM; Evans SB; Su K; Mehta R; Wang SY; Gross CP
    J Natl Compr Canc Netw; 2017 Mar; 15(3):346-354. PubMed ID: 28275035
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.
    Hull LE; Lynch JA; Berse BB; DuVall SL; Chun DS; Venne VL; Efimova OV; Icardi MS; Kelley MJ
    Clin Breast Cancer; 2018 Apr; 18(2):135-143. PubMed ID: 29306660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
    Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence Disparities and Utilization Trends of Oncotype Dx Assay: A National Cancer Database Study.
    Chen S; Thacker C; Wang S; Young KA; Hoffman RL; Blansfield JA
    J Surg Res; 2023 Jun; 286():65-73. PubMed ID: 36758322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor-Positive Breast Cancer.
    Roberts MC; Kurian AW; Petkov VI
    J Natl Compr Canc Netw; 2019 Jun; 17(6):662-668. PubMed ID: 31200352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
    Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
    Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity.
    Moore J; Wang F; Pal T; Reid S; Cai H; Bailey CE; Zheng W; Lipworth L; Shu XO
    Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):821-830. PubMed ID: 35064066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
    Sughayer MA; Alhassoon S; Sughayer HM
    Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.
    Acuna N; Plascak JJ; Tsui J; Stroup AM; Llanos AAM
    Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34065945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
    Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
    Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of 21-Gene Expression Assay on Clinical Outcomes in Node-Negative ≤ T1b Breast Cancer.
    Pomponio M; Keele L; Hilt E; Burkbauer L; Goldbach M; Nazarian S; Fox K; Tchou J
    Ann Surg Oncol; 2020 May; 27(5):1671-1678. PubMed ID: 31686348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
    Baltres A; Al Masry Z; Zemouri R; Valmary-Degano S; Arnould L; Zerhouni N; Devalland C
    Breast Cancer; 2020 Sep; 27(5):1007-1016. PubMed ID: 32385567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial disparities in initiation of chemotherapy among breast cancer patients with discretionary treatment indication in the state of Georgia.
    Collin LJ; Jones J; Nash R; Switchenko JM; Ward KC; McCullough LE
    Breast Cancer Res Treat; 2024 Jun; 205(3):609-618. PubMed ID: 38517602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
    Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
    Chen L; Li CI
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time.
    Williams AD; Reyes SA; Arlow RL; Tchou J; De La Cruz LM
    Ann Surg Oncol; 2018 Oct; 25(10):2875-2883. PubMed ID: 29959613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.